Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%
Lithium
44.28
0.52%
Gold
2,742.60
(0.4%)
Copper
4.29
0.59%
Oil
70.18
(0.35%)
Bitcoin
100,390.06
(0.79%)
FTSE 100
8,315.27
0.16%
Nikkei 225
39,849.14
-0%
Dow Jones
44,148.56
(0.34%)
Iron Ore
105.95
1.31%
USD/AUD
0.64
0.53%
Hang Seng
20,397.05
0.91%

Opthea Ltd

OPT

ASX

Opthea Limited (OPT) develops and commercialize therapies primarily for eye disease. Opthea's lead asset, sozinibercept (OPT-302), is a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3" in clinical development as a novel therapy for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Wet AMD and DME are leading causes of blindness in the elderly and diabetic populations respectively and are increasing in prevalence worldwide.

Latest Posts

Line Chart with Gradient
Price
$0.645
-0.025 (-3.73%)
At Close 11/12 (AEST)
Related Companies
HEXIMA LIMITED.
$HXL
RECCE PHARMACEUTICALS LTD
$RCE
BOTANIX PHARMACEUTICALS LTD
$BOT
NOXOPHARM LIMITED
$NOX
ALTHEA GROUP HOLDINGS LIMITED
$AGH

Leave a Comment on OPT


Comments for OPT

    Latest Posts

    opthea-asx-opt-to-present-at-floretina-congress-opt
    Health Care $OPT
    Opthea (ASX: $OPT) to present at FLORetina congressOpthea will showcase sozinibercept at FLORetina Congress for innovative retinal disease treatments
    November 26, 2024
    Opthea Secures (ASX: $OPT) A$15.9 Million R&D Tax Incentive, Bolstering Financial Position
    Health Care
    $opt
    Opthea Secures (ASX: $OPT) A$15.9 Million R&D Tax Incentive, Bolstering Financial PositionOpthea Limited , a clinical-stage biopharmaceutical company pioneering treatments for retinal diseases, has announced the receipt of an A$15.9 million...
    November 15, 2024
    opthea-asx-opt-reports-quarterly-activity-highlights-opt
    Health Care $OPT
    Opthea (ASX: $OPT) reports quarterly activity highlightsFocus on leadership changes, drug validation, and index inclusion in Q1 FY25
    October 31, 2024
    opthea-asx-opt-advances-pivotal-trials-for-wet-amd-treatment-opt
    Health Care $OPT
    Opthea (ASX: $OPT) advances pivotal trials for wet AMD treatmentOpthea progresses with Phase 3 trials for Sozinibercept aiming to improve outcomes for wet AMD patients
    October 28, 2024
    opthea-asx-opt-joins-sp-asx-300-index-opt
    Health Care $OPT

    Opthea (ASX: $OPT) joins s&p/asx 300 index

    Company strengthens balance sheet and reaches significant milestone in wet AMD program

    September 23, 2024
    opthea-asx-opt-completes-drug-substance-ppq-campaign-validating-manufacturing-process-of-sozinibercept-opt
    Health Care $OPT

    Opthea (ASX: $OPT) completes drug substance ppq campaign validating manufacturing process of sozinibercept

    Opthea achieves major milestone for potential BLA filing in wet AMD

    September 19, 2024
    opthea-asx-opt-targets-superior-vision-gains-in-wet-amd-market-opt
    Health Care $OPT

    Opthea (ASX: $OPT) targets superior vision gains in wet AMD market

    Topline data anticipated for COAST and ShORe trials in early and mid-CY2025

    September 9, 2024
    opthea-asx-opt-completes-a55-9m-retail-entitlement-offer-opt
    Health Care $OPT

    Opthea (ASX: $OPT) completes A$55.9m retail entitlement offer

    Retail entitlement offer raises A$55.9m, new shares and options to commence trading

    July 15, 2024
    opthea-asx-opt-suspends-options-trading-opt
    Health Care $OPT

    Opthea (ASX: $OPT) suspends options trading

    Suspension from quotation with expected normal settlement on July 18, 2024

    July 12, 2024
    opthea-asx-opt-announces-publication-on-vegf-c-and-d-signaling-pathways-as-potential-targets-for-treatment-of-wet-amd-opt
    Health Care $OPT

    Opthea (ASX: $OPT) announces publication on VEGF-C and D signaling pathways as potential targets for treatment of wet AMD

    Research supports sozinibercept's potential as novel VEGF-C/D 'trap' for wet AMD treatment

    July 10, 2024
    opthea-asx-opt-opens-a55-0m-retail-entitlement-offer-opt
    Health Care $OPT

    Opthea (ASX: $OPT) opens A$55.0m retail entitlement offer

    Retail offer to raise funds for clinical development of sozinibercept

    June 20, 2024
    opthea-asx-opt-completes-placement-and-institutional-component-of-entitlement-offer-opt
    Health Care $OPT

    Opthea (ASX: $OPT) completes placement and institutional component of entitlement offer

    Raises A$171.5 million in successful completion of institutional component

    June 14, 2024
    opthea-asx-opt-requests-trading-halt-for-proposed-capital-raising-opt
    Health Care $OPT

    Opthea (ASX: $OPT) requests trading halt for proposed capital raising

    Trading halt requested to manage continuous disclosure obligations

    June 7, 2024
    opthea-asx-opt-advances-sozinibercept-phase-3-trials-for-wet-amd-opt
    Health Care $OPT

    Opthea (ASX: $OPT) advances sozinibercept phase 3 trials for wet AMD

    Completes COAST enrollment, ShORe estimated to complete in Q2 CY2024

    April 5, 2024
    opthea-asx-opt-advances-sozinibercept-for-wet-amd-treatment-opt
    Health Care $OPT

    Opthea (ASX: $OPT) advances sozinibercept for wet AMD treatment

    Completes Phase 3 enrollment, anticipates topline data in mid-CY2025

    April 4, 2024
    opthea-asx-opt-advances-sozinibercept-to-improve-vision-outcomes-opt
    Health Care $OPT

    Opthea (ASX: $OPT) advances sozinibercept to improve vision outcomes

    Completes enrollment in Phase 3 trial and anticipates mid-CY2025 topline data

    March 4, 2024
    opthea-asx-opt-reports-half-year-financial-results-and-business-updates-opt
    Health Care $OPT

    Opthea (ASX: $OPT) reports half-year financial results and business updates

    Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in CY Q2 2024

    February 29, 2024

    OPT

    $OPT

    Opthea (ASX: $OPT) to present at FLORetina congress

    Opthea will showcase sozinibercept at FLORetina Congress for innovative retinal disease treatments

    OPT

    $OPT

    Opthea (ASX: $OPT) reports quarterly activity highlights

    Focus on leadership changes, drug validation, and index inclusion in Q1 FY25

    OPT

    $OPT

    Opthea (ASX: $OPT) advances pivotal trials for wet AMD treatment

    Opthea progresses with Phase 3 trials for Sozinibercept aiming to improve outcomes for wet AMD patients

    OPT

    $OPT

    Opthea (ASX: $OPT) joins s&p/asx 300 index

    Company strengthens balance sheet and reaches significant milestone in wet AMD program

    OPT

    $OPT

    Opthea (ASX: $OPT) completes drug substance ppq campaign validating manufacturing process of sozinibercept

    Opthea achieves major milestone for potential BLA filing in wet AMD

    OPT

    $OPT

    Opthea (ASX: $OPT) targets superior vision gains in wet AMD market

    Topline data anticipated for COAST and ShORe trials in early and mid-CY2025

    OPT

    $OPT

    Opthea (ASX: $OPT) completes A$55.9m retail entitlement offer

    Retail entitlement offer raises A$55.9m, new shares and options to commence trading

    OPT

    $OPT

    Opthea (ASX: $OPT) suspends options trading

    Suspension from quotation with expected normal settlement on July 18, 2024

    OPT

    $OPT

    Opthea (ASX: $OPT) announces publication on VEGF-C and D signaling pathways as potential targets for treatment of wet AMD

    Research supports sozinibercept's potential as novel VEGF-C/D 'trap' for wet AMD treatment

    OPT

    $OPT

    Opthea (ASX: $OPT) opens A$55.0m retail entitlement offer

    Retail offer to raise funds for clinical development of sozinibercept

    Load More
    No More Posts
    Related Companies
    PHARMAUST LIMITED
    $PAA
    NOXOPHARM LIMITED
    $NOX
    HEXIMA LIMITED.
    $HXL
    ANTEOTECH LTD
    $ADO
    MELODIOL GLOBAL HEALTH LIMITED
    $ME1DE

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions